Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas.

[1]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[2]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[3]  R. Mattson.  Medical management of epilepsy in adults , 1998, Neurology.

[4]  J. Witjes,et al.  Bacille Calmette-Guérin in superficial transitional cell carcinoma. , 1998, British journal of urology.

[5]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[6]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[7]  J. Wasson.  Finasteride to prevent morbidity from benign prostatic hyperplasia. , 1998, The New England journal of medicine.

[8]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[9]  P. Boyle,et al.  Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. , 1997, Urology.

[10]  M. Barry,et al.  The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. , 1997, The Journal of urology.

[11]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[12]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[13]  D. Lamm,et al.  Bladder cancer, 1996 , 1996, Ca.

[14]  C. Ed.  Diagnosis and treatment of superficial bladder cancer: an update. , 1996 .

[15]  L K Lloyd,et al.  The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. , 1996, Urology.

[16]  U. Nseyo,et al.  Therapy of superficial bladder cancer. , 1994, Seminars in oncology.

[17]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[18]  D. Lamm.  BCG in perspective: advances in the treatment of superficial bladder cancer. , 1995, European urology.

[19]  J. Birkhoff.  Natural History of Benign Prostatic Hypertrophy , 1983 .

[20]  P. Abrams,et al.  The natural history of untreated "prostatism". , 1981, British journal of urology.

[21]  H H Zinsser,et al.  Natural history of benign prostatic hypertrophy and acute urinary retention. , 1976, Urology.